98%
921
2 minutes
20
Traumatic brain injury (TBI) is a major global health concern and is increasingly recognized as a risk factor for neurodegenerative diseases including Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE). Repetitive TBIs (rTBIs), commonly observed in contact sports, military service, and intimate partner violence (IPV), pose a significant risk for long-term sequelae. To study the long-term consequences of TBI and rTBI, researchers have typically used mammalian models to recapitulate brain injury and neurodegenerative phenotypes. However, there are several limitations to these models, including: (1) lengthy observation periods, (2) high cost, (3) difficult genetic manipulations, and (4) ethical concerns regarding prolonged and repeated injury of a large number of mammals. Aquatic vertebrate model organisms, including (sea lampreys), zebrafish (), (), and (), are emerging as valuable tools for investigating the mechanisms of rTBI and tauopathy. These non-mammalian models offer unique advantages, including genetic tractability, simpler nervous systems, cost-effectiveness, and quick discovery-based approaches and high-throughput screens for therapeutics, which facilitate the study of rTBI-induced neurodegeneration and tau-related pathology. Here, we explore the use of non-vertebrate and aquatic vertebrate models to study TBI and neurodegeneration. , in particular, provides an opportunity to explore the longitudinal effects of mild rTBI and its impact on endogenous tau, thereby offering valuable insights into the complex interplay between rTBI, tauopathy, and neurodegeneration. These models provide a platform for mechanistic studies and therapeutic interventions, ultimately advancing our understanding of the long-term consequences associated with rTBI and potential avenues for intervention.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985199 | PMC |
http://dx.doi.org/10.3389/fneur.2024.1378620 | DOI Listing |
Mol Cancer Ther
September 2025
University of Pittsburgh, Pittsburgh, PA, United States.
Ewing sarcoma (EwS) is an aggressive bone and soft tissue cancer affecting adolescents and young adults. In vitro and in vivo models of EwS have been instrumental in advancing our understanding of EwS biology and essential in evaluating potential therapies, particularly for metastatic or relapsed disease where effective treatment options remain limited. Through an international collaborative effort between the Children's Oncology Group (COG) Bone Tumor Committee and the Euro Ewing Consortium (EEC), we review the current landscape of preclinical modeling used in EwS research encompassing both in vitro (cell lines and tumor organoids) and in vivo (mouse and non-mammalian xenografts) model systems.
View Article and Find Full Text PDFFront Syst Neurosci
August 2025
Department of Chemistry, Acadia University, Wolfville, NS, Canada.
Psilocybin, a compound found in mushrooms, is emerging as a promising treatment for neurodegenerative and psychiatric disorders, including major depressive disorder. Its potential therapeutic effects stem from promoting neuroprotection, neurogenesis, and neuroplasticity, key factors in brain health. Psilocybin could help combat mild neurodegeneration by increasing synaptic density and supporting neuronal growth.
View Article and Find Full Text PDFInsect Sci
August 2025
School of Life Sciences, Anhui Agricultural University, Hefei, China.
Dihydrofolate reductase (DHFR), a pivotal enzyme in folate metabolism and DNA synthesis, is a well-established cancer therapeutic target. However, its non-canonical roles in developmental signaling and evolutionary-conserved functions in non-mammalian species remain poorly characterized. Using the lepidopteran model Bombyx mori, this study uncovered the pleiotropic functions of BmDHFR in midgut proliferation and lipid homeostasis through dual metabolic and Hedgehog (Hh) signaling regulation.
View Article and Find Full Text PDFEur J Neurosci
August 2025
Department of Biosciences and Bioinformatics, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China.
Mismatch negativity (MMN), first described by Risto Näätänen in the late 1970s, is now known as a key phenomenon in the brain, reflecting its ability to detect differences in the presented sensory stimuli. Although MMN has been widely studied in both humans and other mammals, the phenomenon has also been increasingly examined in non-mammalian species in recent years. Here, we discuss the role of MMN as an evolutionarily conserved phenotype across taxa, and its general translational significance in neuroscience.
View Article and Find Full Text PDFFront Vet Sci
July 2025
Exubrion Therapeutics, Inc., Gainesville, GA, United States.
Osteoarthritis (OA) is a progressive joint disorder affecting mammals as well as many non-mammalian animals, characterized by cartilage degradation and synovial inflammation, yet current treatments focus solely on symptom relief rather than disease modification. Radiosynoviorthesis (RSO) using commercially available homogeneous Sn-117m microparticles (HTM) (Synovetin OA®, Exubrion Therapeutics, Inc.) injected into the arthritic joint space targets synovitis-a critical driver of OA progression-offering a novel therapeutic approach.
View Article and Find Full Text PDF